For example, a randomized controlled trial (RCT) of patients with severe COVID-19 who were referred for ECMO reported that the Cytosorb (CytoSorbents, NJ, USA) treatment group not only failed to reduce IL-6 but also had a significantly higher 30-day mortality rate25 Questions regarding randomization, timing of ECMO, and serum IL-6 levels have been raised, and no conclusions can be drawn. This evidence concerns the gene IL6 and COVID-19.